Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Change in Account Payables (2016 - 2021)

Historic Change in Account Payables for Lexaria Bioscience (LEXX) over the last 11 years, with Q4 2021 value amounting to -$5223.0.

  • Lexaria Bioscience's Change in Account Payables fell 11833.85% to -$5223.0 in Q4 2021 from the same period last year, while for Aug 2022 it was -$5223.0, marking a year-over-year increase of 9023.39%. This contributed to the annual value of -$5223.0 for FY2022, which is 9023.39% up from last year.
  • Per Lexaria Bioscience's latest filing, its Change in Account Payables stood at -$5223.0 for Q4 2021, which was down 11833.85% from $3899.0 recorded in Q3 2021.
  • Lexaria Bioscience's 5-year Change in Account Payables high stood at $119621.0 for Q1 2021, and its period low was -$243169.0 during Q2 2017.
  • Its 5-year average for Change in Account Payables is -$16399.6, with a median of $1130.5 in 2018.
  • In the last 5 years, Lexaria Bioscience's Change in Account Payables plummeted by 285733.08% in 2017 and then soared by 225944.22% in 2019.
  • Quarter analysis of 5 years shows Lexaria Bioscience's Change in Account Payables stood at -$17672.0 in 2017, then skyrocketed by 178.08% to $13799.0 in 2018, then plummeted by 178.96% to -$10896.0 in 2019, then soared by 361.39% to $28481.0 in 2020, then tumbled by 118.34% to -$5223.0 in 2021.
  • Its Change in Account Payables was -$5223.0 in Q4 2021, compared to $3899.0 in Q3 2021 and -$205482.0 in Q2 2021.